CLINICAL_TRIALS trial_result · 2014-01-30

Clinical Trial Update: Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis [Phase 2]

Phase 2 dose-ranging trial of OPC-249 powder inhalation in patients with pain due to osteoporosis completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Pain Due to Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2014-01-30